A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.
An Open-label Study to Evaluate the Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17-deacetylnorgestimate and Ethinyl Estradiol With the Oral Contraceptive Triphasil.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, nonpregnant women with regular menstrual cycles
- sexually active and at risk of pregnancy
- acceptable body mass index (BMI)
- last term pregnancy at least 42 days prior, nonlactating, with 1 normal menstrual cycle since
- sitting BP<140mmHg/<90mmHg
- 1 normal menstrual cycle since removal of IUD or norplant
- agreement to use study drug for contraception for up to 13 cycles, except when backup contraception is required for disease protection or patch detachment
- agree not to use other systemic steroid medication
Exclusion Criteria:
- Presence, history, hereditary predisposition or risk of deep vein thrombophlebitis or thromboembolic disorders
- cerebral vascular or coronary artery disease, hypertension, or severe migraines
- liver tumor resulting from estrogen-containing products
- diabetes mellitus
- cholestatic jaundice, liver or renal disease
- abnormal PAP smear
- undiagnosed abnormal vaginal bleeding
- thyroid disorder
- dermal hypersensitivity
- carcinoma of breast, genital tract or other estrogen-dependent neoplasia
- received any depot hormone injection within prior 6 months
- smoking women over 35 years of age.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Contraceptive efficacy of the 2 treatments was estimated by determination of pregnancy rates, using the Pearl Index and life table analysis (cumulative probability of pregnancy). Safety was evaluated throughout the study.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Cycle control and compliance were assessed with diary cards containing bleeding and dosing information.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002 Feb;77(2 Suppl 2):S13-8. doi: 10.1016/s0015-0282(01)03275-7.
- Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, Creasy GW. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril. 2002 Feb;77(2 Suppl 2):S32-5. doi: 10.1016/s0015-0282(01)03262-9.
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral, Combined
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Contraceptives, Postcoital, Synthetic
- Contraceptives, Postcoital
- Contraceptives, Postcoital, Hormonal
- Estradiol
- Ethinyl Estradiol
- Ethinyl Estradiol-Norgestrel Combination
- Norelgestromin
Other Study ID Numbers
Other Study ID Numbers
- CR005506
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.